NEPH vs NX

For growth investors, Quanex Building Products Corporation (NX) is the stronger pick with 43.

8% revenue growth year-over-year, versus 32. 7% for Nephros, Inc. (NEPH). Nephros, Inc. (NEPH) offers the better valuation at 29. 4x trailing P/E, making it the more compelling value choice. Analysts rate Quanex Building Products Corporation (NX) a "Hold" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Quanex Building Products Corporation (NX) delivered a total return of -22.

0%, compared to -56. 3% for Nephros, Inc. (NEPH). Over 10 years, the gap is even starker: NX returned +24. 7% versus NEPH's +11. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nephros, Inc.

(NEPH) is the lower-risk stock at 0. 58β versus Quanex Building Products Corporation's 1. 83β — meaning NX is approximately 218% more volatile than NEPH relative to the S&P 500. On balance sheet safety, Nephros, Inc. (NEPH) carries a lower debt/equity ratio of 10% versus 118% for Quanex Building Products Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Quanex Building Products Corporation (NX) is pulling ahead at 43.

8% versus 32. 7% for Nephros, Inc. (NEPH). Over a 3-year CAGR, NEPH leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nephros, Inc.

(NEPH) is the more profitable company, earning 6. 4% net margin versus -13. 6% for Quanex Building Products Corporation — meaning it keeps 6. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NEPH leads at 6. 1% versus -10. 6% for NX. At the gross margin level — before operating expenses — NEPH leads at 61. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, NX (1.

6% yield) pays a dividend. NEPH does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Nephros, Inc.

(NEPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 58)). Quanex Building Products Corporation (NX) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NEPH: +11. 7%, NX: +24. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NEPH (Healthcare) and NX (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

NX pays a dividend while NEPH does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.